
Steven J Swanson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10909673/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods, 2004, 289, 1-16.	1.4	576
2	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. Journal of Immunological Methods, 2008, 333, 1-9.	1.4	326
3	Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. Journal of Immunological Methods, 2007, 321, 1-18.	1.4	225
4	Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab. Journal of Immunology, 2007, 178, 7467-7472.	0.8	181
5	An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. Journal of Immunological Methods, 2005, 304, 189-195.	1.4	178
6	Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin. Nephron Clinical Practice, 2004, 96, c88-c95.	2.3	85
7	Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. Journal of Immunological Methods, 2006, 308, 101-108.	1.4	78
8	Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeutic Human Monoclonal Antibodies. Clinical Chemistry, 2005, 51, 1983-1985.	3.2	74
9	Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson's Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion. Journal of Clinical Immunology, 2007, 27, 620-627.	3.8	64
10	Validation parameters for a novel biosensor assay which simultaneously measures serum concentrations of a humanized monoclonal antibody and detects induced antibodies. Journal of Immunological Methods, 1997, 209, 1-15.	1.4	57
11	Identification and inhibition of drug target interference in immunogenicity assays. Journal of Immunological Methods, 2010, 355, 21-28.	1.4	57
12	Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. Journal of Immunological Methods, 2010, 357, 10-16.	1.4	57
13	Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Current Medical Research and Opinion, 2003, 19, 651-659.	1.9	54
14	Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins. Vaccine Journal, 2005, 12, 28-39.	3.1	42
15	The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 415-426.	2.8	41
16	Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. Journal of Immunological Methods, 2004, 293, 115-126.	1.4	39
17	Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrology Dialysis Transplantation, 2005, 20, iv16-iv22.	0.7	37
18	Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics. AAPS Journal, 2013, 15, 30-40.	4.4	37

STEVEN J SWANSON

#	Article	IF	CITATIONS
19	Immunogenicity assessment in non-clinical studies. Current Opinion in Microbiology, 2012, 15, 337-347.	5.1	34
20	Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. Journal of Immunological Methods, 2013, 396, 44-55.	1.4	34
21	lmmunogenicity testing strategy and bioanalytical assays for antibody–drug conjugates. Bioanalysis, 2013, 5, 1041-1055.	1.5	33
22	Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge. Biotechnology Annual Review, 2004, 10, 237-250.	2.1	29
23	Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Annals of Hematology, 2010, 89, 75-85.	1.8	28
24	Detection and Characterization of Antibodies to PEG-IFN-alpha2b Using Surface Plasmon Resonance. Journal of Interferon and Cytokine Research, 1999, 19, 781-789.	1.2	27
25	Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis, 2014, 6, 1509-1523.	1.5	27
26	Characteristics of the binding of human C-reactive protein (CRP) to laminin. Journal of Cellular Biochemistry, 1989, 40, 121-132.	2.6	26
27	Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clinical Pharmacology, 2011, 11, 17.	2.5	23
28	Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrology Dialysis Transplantation, 2012, 27, 688-693.	0.7	22
29	Binding and immunological properties of a synthetic peptide corresponding to the phosphorylcholine-binding region of C-reactive protein. Molecular Immunology, 1990, 27, 679-687.	2.2	21
30	Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. Journal of Immunological Methods, 2012, 382, 93-100.	1.4	19
31	Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1265-1274.	2.8	18
32	Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. Journal of Immunological Methods, 2012, 382, 129-141.	1.4	18
33	Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis, 2010, 2, 721-731.	1.5	16
34	Kinetics of maltose hydrolysis by glucoamylase. Biotechnology and Bioengineering, 1977, 19, 1715-1718.	3.3	15
35	Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). BBA - Proteins and Proteomics, 1992, 1160, 309-316.	2.1	15
36	Immunogenicity Issues in Drug Development. Journal of Immunotoxicology, 2006, 3, 165-172.	1.7	15

STEVEN J SWANSON

#	Article	IF	CITATIONS
37	Assessing specificity for immunogenicity assays. Bioanalysis, 2009, 1, 611-617.	1.5	15
38	Pore diffusion in packed-bed reactors containing immobilized glucoamylase. AICHE Journal, 1978, 24, 30-34.	3.6	13
39	Feasibility of a Multiplex Flow Cytometric Bead Immunoassay for Detection of Anti-Epoetin Alfa Antibodies. Vaccine Journal, 2007, 14, 1165-1172.	3.1	13
40	A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. Journal of Immunological Methods, 2006, 316, 8-17.	1.4	11
41	Comparing Exponentially Weighted Moving Average and Run Rules in Process Control of Semiquantitative Immunogenicity Immunoassays. AAPS Journal, 2010, 12, 79-86.	4.4	8
42	A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development. AAPS Journal, 2009, 11, 526-34.	4.4	6
43	Immunogenicity Issues in the Development of Therapeutic Proteins. Pharmaceutical Medicine, 2007, 21, 207-216.	0.4	5
44	A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 583-589.	2.8	5
45	Immunogenicity of Therapeutic Proteins. , 2010, , 105-117.		0
46	Clinical Manifestations of an Anti-Drug Antibody Response: Autoimmune Reactions. Journal of Interferon and Cytokine Research, 2014, 34, 953-957.	1.2	0